Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Celularity Inc CELUW


Primary Symbol: CELU

Financial Services Healthcare Biotechnology
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn’s disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and... see more

Current News (NDAQ:CELU)

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

GlobeNewswire 5 days ago

Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations

GlobeNewswire December 26, 2025

Celularity Announces Closing of Financing Transactions

GlobeNewswire December 22, 2025

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

GlobeNewswire December 18, 2025

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care

GlobeNewswire October 30, 2025

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

GlobeNewswire October 14, 2025

Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

GlobeNewswire September 3, 2025

Celularity Receives Nasdaq Notice Regarding Form 10-Q

GlobeNewswire August 22, 2025

Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt

GlobeNewswire August 18, 2025
View More News ››

Opinion & Analysis (NDAQ:CELU)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CELU)

Using technical analysis for this stock.

It is signalling a big upswing for shareholders today anyway,so good luck to all
coolfooldumbguy - July 15, 2025

RE:CELU.....Pop goes the weasel

Oops....typo...s/b $2.70 Lo Siento !!!
Iseneschal - February 5, 2025

CELU.....Pop goes the weasel

$3.70
Iseneschal - February 5, 2025

CELU....on watch @ $2.45

Cheers !
Iseneschal - February 5, 2025

Celularity Inc. (NASDAQ:CELU): Placental-Derived Allogeneic

http://beyondspx.com/2024/08/01/celularity-inc-nasdaqcelu-placental-derived-allogeneic-cell-therapies-and-advanced-biomaterial-products...
MikeTester - August 1, 2024
View more Bullboard ››

Southern Silver Exploration Corp.

Southern Silver Exploration Corp.

Southern Silver Exploration Corp., an exploration stage company, acquires, explores, and develops natural resource properties ...
View More »

Podcasts